This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $28, marking a +1.97% move from the previous day.
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Medicine (EDIT) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $25.98, moving -0.95% from the previous trading session.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Top Performing Active ETFs & Tesla's Best-Case Scenario
by Neena Mishra
Neena Mishra talks with COO of ARK Investment Management, the firm behind most innovative ETFs that have consistently delivered excellent performance.
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
by Zacks Equity Research
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Editas Medicine (EDIT) Enters Oversold Territory
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) has been on a bit of a cold streak lately
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?